Researchers to Test Targeted Treatment for Prostate Cancer

CINCINNATI—The American Cancer Society estimates one man in six will get prostate cancer during his lifetime, making it the second-leading cause of cancer death in men.

The American Cancer Society estimates one man in six will get prostate cancer during his lifetime, making it the second-leading cause of cancer death in men. With a new partnership with Areva Med, UC researchers will investigate the use of a new drug in stopping the growth of prostate cancer tumors.

In the study, UC researchers in the lab of Zhongyun Dong, PhD, will test the efficacy of a new agent targeted against a specific protein on the surface of the tumor.

Prostate Cancer | Cancer of Prostate - Incidence, Prevention, Causes, Symptoms & Treatment
This cancer affects men over the age of 50 years and screening with rectal examination and PSA can help both in early detection and effective treatment

"It's been shown that human prostate cancer cells overexpress some proteins on their surface," says Dong, an associate professor of hematology oncology in the department of internal medicine. "This overexpression presents a novel target for management of advanced prostate cancer."

Dong says previous radiation therapy targeting these proteins has been shown to inhibit tumor growth in several animal models. UC's study will be the first to explore this approach for prostate tumors. In the work, researchers will bind the isotope 212-lead to an antibody targeting one of these proteins.

"When administered intravenously, the AREVA Med 2120lead-antibody is designed to bind to the tumor's surface, emit alpha particles in and selectively destroy the tumor cells," says Dong.

Surgery of prostate gland
Interactive section of Medindia gives information regarding Surgery of prostate gland

In the study, expected to run through the end of the year, researchers will measure the toxicity of the treatment and its efficacy in inhibiting cancer cell growth. Data will then be gathered to support phase-1 clinical trials in patients with advanced prostate cancer.

According to hematology oncology professor Olivier Rixe, MD, PhD, the agent represents a more targeted radiation therapy for cancer treatment. Rixe is the director of the UC's recently launched phase-1 clinical trials unit at the newly established Early Drug Development Program.

Quiz on Prostate Cancer
Prostate cancer is fast gaining as a common cancer form among men; more threatening since its symptoms often go unnoticed until it’s too late. This quiz tests your knowledge on prostate cancer, its diagnosis and treatment options and is as mandatory for men as the screening tests mentioned here are!

"Targeting a monoclonal antibody against this protein is not new," says Rixe. "What's new is that we will load the antibody with an isotope that can directly target the protein on the cancer cell and deliver very localized radiation to this specific target of the cancer.

"It's a very interesting concept for drug delivery and a novel strategy for cancer treatment."

Source-Eurekalert
SRM